Healthcare / BiotechnologyNasdaqGM
$3.53
-0.24 (-6.37%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $13.7M · quality 53.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
44/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.1B
P/E
176.5x
↑EV/EBITDA
27.2x
↑ROE
-11.5%
↓Gross Margin
74.8%
↑Debt/Equity
-7.20
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
1992–2025 · 33 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
3.9%
FCF / Net income
2.33x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $349.0M · net income $5.9M · FCF $13.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||||||||||||||||||||||||
| Revenue | $349.0M | $349.0M | $285.5M | $199.0M | $99.8M | $75.4M | $65.1M | $63.0M | $27.9M | $11.7M | $174.8M | $0.00 | $0.00 | $0.00 | $35000.00 | $50000.00 | $93000.00 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net Income | $5.9M | $5.9M | $27.6M | $-11.9M | $-87.4M | $-80.9M | $-57.2M | $-51.9M | $-87.0M | $-117.3M | $125.7M | $-368.4M | $-198.4M | $-191.5M | $-169.4M | $-160.8M | $-170.6M | $-220.1M | $-303.0M | $-293.2M | $-230.5M | $-114.3M | $-76.0M | $-65.9M | $-206.3M | $-48.2M | $-24.7M | $-5.7M | $-3.3M | $-2.3M | $-2.6M | $-2.8M | $-2.0M | $-1.2M | $-911000.00 |
| EBITDA | $51.5M | $51.5M | $75.7M | $19.1M | $-56.3M | $-45.0M | $-45.8M | $-43.6M | $-73.7M | $-106.4M | $69.7M | $-333.7M | $-169.8M | $-157.9M | $-134.0M | $-125.9M | $-136.0M | $-191.1M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS | 0.02 | 0.02 | 0.10 | -0.04 | -0.34 | -0.32 | -0.26 | — | -0.60 | -1.13 | 1.36 | -4.54 | -2.57 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Gross Margin | 74.8% | 74.8% | 73.2% | 68.5% | 42.4% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | 13.3% | 13.3% | 24.1% | 5.3% | -69.1% | -62.3% | -73.5% | -70.7% | -274.9% | -921.1% | 38.5% | — | — | — | -419885.7% | -281078.0% | -163976.3% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net Margin | 1.7% | 1.7% | 9.7% | -6.0% | -87.6% | -107.3% | -87.9% | -82.3% | -312.2% | -999.0% | 71.9% | — | — | — | -483902.9% | -321608.0% | -183397.8% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Balance Sheet | |||||||||||||||||||||||||||||||||||
| Debt/Equity | -7.20 | -7.20 | -0.64 | -1.11 | -1.11 | -1.34 | -0.68 | -0.62 | -0.59 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Current Ratio | 1.87 | 1.87 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||||||||||||||||||||||||||
| Free Cash Flow | $13.7M | $13.7M | $32.8M | $-8.3M | $-88.3M | $-73.2M | $-28.9M | $-91.0M | $-38.1M | — | $-79.2M | — | — | $-1.73B | $-120.5M | $-130.7M | $-158.2M | $-202.9M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Returns | |||||||||||||||||||||||||||||||||||
| ROE | -11.5% | -11.5% | -35.0% | 4.8% | 34.9% | 38.7% | 31.7% | 27.2% | 49.7% | 54.6% | -68.4% | 105.2% | 268.9% | 623.5% | 153.0% | 51.3% | 91.9% | 371.7% | -349.4% | -80.5% | -60.1% | -55.2% | -50.5% | -59.0% | -227.2% | -20.5% | -77.3% | 761.3% | -97.9% | 30.9% | 46.9% | 90.6% | 283.5% | 422.7% | 8281.8% |
| Valuation | |||||||||||||||||||||||||||||||||||
| P/E | 176.50 | 176.50 | 64.80 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EV/EBITDA | 27.20 | 27.20 | 24.36 | 52.64 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | |||||||||||||||||||||||||||||||||||
| Revenue Growth | 22.2% | 22.2% | 43.5% | 99.4% | — | 15.8% | 3.3% | 126.3% | 137.2% | -93.3% | — | — | — | -100.0% | -30.0% | -46.2% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS Growth | -80.0% | -80.0% | 350.0% | 88.2% | — | -23.1% | — | — | 46.9% | -183.1% | 130.0% | -76.7% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
150.2%
EPS terminal req.
$0.31
Spread vs growth
-230.2%
5Y implied EPS CAGR
80.1%
EPS terminal req.
$0.38
Spread vs growth
-160.1%
10Y implied EPS CAGR
40.8%
EPS terminal req.
$0.61
Spread vs growth
-120.8%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-14.9%
Start / end P/E
41.5x → 176.5x
EPS bridge
0.10 → 0.02
Residual
-260.2%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.